Literature DB >> 2462388

Capreomycin kinetics in renal impairment and clearance by hemodialysis.

C R Lehmann1, L E Garrett, R E Winn, P D Springberg, S Vicks, D K Porter, W P Pierson, J D Wolny, G L Brier, H R Black.   

Abstract

The single-dose kinetics of capreomycin are described for 12 renal patients and seven healthy control subjects. Creatinine clearances (CrCl) ranged from zero to 121 ml/min. After single-dose intravenous infusions, mean +/- SD capreomycin clearance values (L/kg/h x 10(-2)) were 0.558 +/- 0.160 for the dialysis group (n = 4, CrCl = 1.4 +/- 1.9), 1.77 +/- 0.45 for the moderate renal group (n = 3, CrCl = 25 +/- 5), 2.82 +/- 1.52 for the mild renal group (n = 4, CrCl = 46 +/- 5), and 5.73 +/- 1.54 for the normal renal group (n = 7, CrCl = 109 +/- 11); p less than 0.01, using analysis of variance. The correlation between capreomycin clearance and CrCl was r = 0.90. Hemodialysis cleared clinically significant amounts of capreomycin. These data imply that capreomycin maintenance doses need to be reduced for renal patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2462388     DOI: 10.1164/ajrccm/138.5.1312

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  3 in total

1.  Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs.

Authors:  L Garcia-Contreras; Pavan Muttil; John K Fallon; Mohan Kabadi; Robert Gerety; Anthony J Hickey
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

2.  Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model.

Authors:  L Garcia-Contreras; J Fiegel; M J Telko; K Elbert; A Hawi; M Thomas; J VerBerkmoes; W A Germishuizen; P B Fourie; A J Hickey; D Edwards
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

Review 3.  Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure.

Authors:  Vincent Launay-Vacher; Hassane Izzedine; Gilbert Deray
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.